ClinicalTrials.gg
CompletedNCT01750190Updated Oct 1, 2021Results posted

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

A Phase 3 interventional study of Roxadustat and Placebo in CKD Anemia, sponsored by FibroGen. Completed at 145 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
922
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
4th of 43
922 · median 154
Started
2012
with 1 other
Phase 3
25 of 43
1 open now
Registered
9th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 25 in phase 3, and was the 9th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants with chronic kidney disease and not on dialysis.

Read the detailed description

There is a screening period of up to 6 weeks, a variable treatment period for individual participants. In order to complete the treatment period simultaneously for all study participants, the minimum treatment duration may be less than 52 weeks, with a maximum treatment duration of up to 3 years after the last participant is randomized, and a post-treatment follow-up period of 4 weeks. Participants who prematurely discontinued from treatment will be expected to complete the Early Termination (ET) and End of Study (EOS) visits. Such participants will be considered non-completers, but they will be expected to participate in long-term follow-up (LTFU) for cardiovascular events (CV) of interest, vital status, and hospitalizations until overall study closure unless the participant withdrew consent for this LTFU data collection. Participants were randomized in a 2:1 ratio to receive either roxadustat or placebo in a double-blind manner.

03

Conditions studied

  • CKD Anemia

Keywords

  • anemia
  • chronic kidney disease (CKD)
  • non-dialysis
  • Hemoglobin (Hb)
  • End-Stage Renal Disease
  • erythropoeitin
  • ASP1517
  • erythropoeisis stimulating-agent
  • AZD9941
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic kidney disease Stages 3, 4, or 5 and not receiving dialysis
  • Anemia qualified by measurements of values during screening
  • Additional blood work must be in a safe range for study entry
  • Body weight 45 to 160 kilograms (kg)
  • Willingness to use if of

Exclusion criteria

Exclusion Criteria:

  • Treatment with an erythropoiesis-stimulating agent (ESA) within 12 weeks prior to study participation
  • More than 1 dose of intravenous iron within 12 weeks prior to study participation
  • Blood transfusion within 8 weeks prior to study participation
  • Active infection
  • Chronic liver disease
  • Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot
  • Uncontrolled blood pressure within 2 weeks prior to study participation
  • Renal cell carcinoma
  • History of , including multiple myeloma or other myelodysplastic syndrome
  • Chronic inflammatory disease that could impact red blood cell production
  • Any prior organ transplant or a scheduled organ transplantation
  • Anticipated elective surgery that is expected to lead to significant blood loss or anticipated elective heart procedure
  • Gastrointestinal bleeding
  • Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
  • Recent use of an drug or treatment, or participation in an investigational study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
922 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing \<70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.

    Drug: Roxadustat

  • Placebo comparator
    Placebo

    Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing \<70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.

    Drug: Placebo

Interventions

  • Oral tablets

    Also known as: FG-4592, ASP1517, AZD9941

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy

    The change in Hb from baseline to the average level during the evaluation period (defined as Week 28 until Week 52) is reported. Hb values under the influence of a rescue therapy were not censored. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.

    Time frame: Baseline (Day 1, Week 0), Weeks 28 to 52

  2. Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy

    The number of participants who achieved a Hb response at 2 consecutive visits at least 5 days apart during the first 24 weeks of treatment, without rescue therapy (that is, red blood cell \[RBC\] transfusion, erythropoiesis-stimulating agent \[ESA\], or intravenous \[IV\] iron) are reported. A Hb response is defined, using central laboratory values, as the following: * Hb ≥11 g/dL and Hb increase from baseline by ≥1 g/dL in participants with baseline Hb \>8 g/dL, or * An increase in Hb by ≥2 g/dL in participants with baseline Hb ≤8.0 g/dL

    Time frame: Baseline up to Week 24

Secondary outcomes

  1. Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy

    For Ex-US submission only: Hb values under the influence of a rescue therapy were censored by mixed effect model of repeated measures (MMRM) for up to 6 weeks. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.

    Time frame: Baseline (Day 1, Week 0), Weeks 28 to 36

  2. Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN)

    Hb values under the influence of a rescue therapy were not censored in the analysis. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study treatment.

    Time frame: Baseline (Day 1, Week 0), Weeks 28 to 52

  3. Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy

    Hb values under the influence of a rescue therapy were censored by Cochran-Mantel-Haenszel Test for up to 6 weeks. Responder was defined as: Hb ≥10.0 g/dL, which was based on central laboratory values.

    Time frame: Weeks 28 to 36

  4. Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28

    Baseline LDL cholesterol was defined as the last LDL cholesterol value prior to the first dose of study drug.

    Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28

  5. Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)

    Progression of chronic kidney disease was measured by rate of change in eGFR over time adjusted by baseline eGFR, with censoring for chronic dialysis or kidney transplant, using random slope and intercept model. Least Square Mean of change from baseline at 1 year was derived based on a random slopes and intercepts model using all available eGFR values (1 baseline and all post-treatment values up to end of treatment period + 7 days or start of dialysis) adjusted on treatment, baseline Hb, baseline eGFR, geographical region, cardiovascular events history at Baseline (yes vs. no), time (continuous value), the interaction terms of baseline eGFR by time, baseline Hb by time, and treatment by time as fixed effects, with random effects of intercept and linear slope of time. All assessments collected after the start of stable dialysis or kidney transplant were excluded from the analysis.

    Time frame: Baseline, Month 12

  6. Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment

    Participants with any use of blood/RBC transfusion were reported.

    Time frame: Baseline up to Week 52

  7. Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment

    Rescue therapy included any use of RBC transfusion, ESA, or IV iron.

    Time frame: Baseline (Day 1, Week 0) up to Week 24 and up to Week 52

  8. Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28

    The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). A higher score indicates a general improvement of life quality or well-being. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.

    Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28

  9. Number (%) of Participants Who Experienced Exacerbation of Hypertension

    Exacerbation of hypertension was defined as an increase from baseline of ≥20 millimeter of mercury (mmHg) in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥110 mmHg.

    Time frame: Baseline up to Week 52

  10. Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28

    Baseline MAP was defined as the last MAP value prior to the first dose of study drug.

    Time frame: Baseline, Weeks 20 to 28

07

Results

Posted Oct 1, 2021

Participant flow

Participant flow — Overall Study
MilestoneRoxadustatPlacebo
Started616306
Safety population611305
Full analysis set (fas)608305
Completed34998
Not completed267208
Withdrew: Adverse event4719
Withdrew: Death3811
Withdrew: Lack of efficacy (including erythropoiesis-stimulating agent rescue)243
Withdrew: Lost to follow-up287
Withdrew: Physician decision1617
Withdrew: Protocol violation65
Withdrew: Study/site terminated by sponsor41
Withdrew: Withdrawal by subject8389
Withdrew: Kidney transplant84
Withdrew: Dialysis228
Withdrew: Other than specified134

Outcome measures

PrimaryUnited States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy

The change in Hb from baseline to the average level during the evaluation period (defined as Week 28 until Week 52) is reported. Hb values under the influence of a rescue therapy were not censored. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.

Time frame:
Baseline (Day 1, Week 0), Weeks 28 to 52
Reported as:
Mean · g/dL
United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy
g/dLRoxadustatPlacebo
Baseline9.10 ± 0.759.09 ± 0.69
Change at Weeks 28 to 522.00 ± 0.9520.16 ± 0.895
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.0001 · Least square mean difference: 1.85 · 95% CI 1.735 to 1.967Roxadustat - Placebo Treatment Difference
PrimaryEx-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy

The number of participants who achieved a Hb response at 2 consecutive visits at least 5 days apart during the first 24 weeks of treatment, without rescue therapy (that is, red blood cell \[RBC\] transfusion, erythropoiesis-stimulating agent \[ESA\], or intravenous \[IV\] iron) are reported. A Hb response is defined, using central laboratory values, as the following: * Hb ≥11 g/dL and Hb increase from baseline by ≥1 g/dL in participants with baseline Hb \>8 g/dL, or * An increase in Hb by ≥2 g/dL in participants with baseline Hb ≤8.0 g/dL

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy
ParticipantsRoxadustatPlacebo
Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy52320
Statistical analysis
  • Roxadustat vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 77.56 · 95% CI 44.73 to 134.48Roxadustat/Placebo Odds ratio
SecondaryMean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy

For Ex-US submission only: Hb values under the influence of a rescue therapy were censored by mixed effect model of repeated measures (MMRM) for up to 6 weeks. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.

Time frame:
Baseline (Day 1, Week 0), Weeks 28 to 36
Reported as:
Mean · g/dL
Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy
g/dLRoxadustatPlacebo
Baseline9.09 ± 0.7499.09 ± 0.694
Change at Weeks 28 to 362.02 ± 1.0670.20 ± 0.994
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.0001 · Least square mean difference: 1.88 · 95% CI 1.730 to 2.037Roxadustat - placebo treatment difference
SecondaryMean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN)

Hb values under the influence of a rescue therapy were not censored in the analysis. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study treatment.

Time frame:
Baseline (Day 1, Week 0), Weeks 28 to 52
Reported as:
Mean · g/dL
Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN)
g/dLRoxadustatPlacebo
Baseline9.10 ± 0.7508.99 ± 0.668
Change at Weeks 28 to 522.02 ± 0.9330.18 ± 0.946
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.0001 · Least square mean difference: 1.90 · 95% CI 1.663 to 2.143Roxadustat - placebo treatment difference
SecondaryNumber (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy

Hb values under the influence of a rescue therapy were censored by Cochran-Mantel-Haenszel Test for up to 6 weeks. Responder was defined as: Hb ≥10.0 g/dL, which was based on central laboratory values.

Time frame:
Weeks 28 to 36
Reported as:
Count of participants · Participants
Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy
ParticipantsRoxadustatPlacebo
Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy46756
Statistical analysis
  • Roxadustat vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 15.47 · 95% CI 10.79 to 22.189Roxadustat/placebo odds ratio
SecondaryMean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28

Baseline LDL cholesterol was defined as the last LDL cholesterol value prior to the first dose of study drug.

Time frame:
Baseline (Day 1, Week 0), Weeks 12 to 28
Reported as:
Mean · mg/dL
Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28
mg/dLRoxadustatPlacebo
Baseline97.74 ± 39.0996.39 ± 40.06
Change at Weeks 12 to 28-18.48 ± 29.600.22 ± 29.37
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -17.26 · 95% CI -20.65 to -13.87Roxadustat- placebo treatment difference
SecondaryRate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)

Progression of chronic kidney disease was measured by rate of change in eGFR over time adjusted by baseline eGFR, with censoring for chronic dialysis or kidney transplant, using random slope and intercept model. Least Square Mean of change from baseline at 1 year was derived based on a random slopes and intercepts model using all available eGFR values (1 baseline and all post-treatment values up to end of treatment period + 7 days or start of dialysis) adjusted on treatment, baseline Hb, baseline eGFR, geographical region, cardiovascular events history at Baseline (yes vs. no), time (continuous value), the interaction terms of baseline eGFR by time, baseline Hb by time, and treatment by time as fixed effects, with random effects of intercept and linear slope of time. All assessments collected after the start of stable dialysis or kidney transplant were excluded from the analysis.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · ml/min/1.73 m^2
Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)
ml/min/1.73 m^2RoxadustatPlacebo
Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)-2.89 ± 0.363-3.10 ± 0.388
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = 0.6924 · Least square mean difference: 0.21 · 95% CI -0.827 to 1.245Roxadustat - placebo treatment difference
SecondaryNumber of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment

Participants with any use of blood/RBC transfusion were reported.

Time frame:
Baseline up to Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment
ParticipantsRoxadustatPlacebo
Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment3447
Statistical analysis
  • Roxadustat vs Placebo · Cox Proportional hazards model · p = <0.0001 (From a Cox Proportional hazards model adjusting for baseline Hb, baseline eGFR and other randomization stratification factors, except baseline Hb (≤8 g/dL versus \>8 g/dL) and eGFR (\<30 versus ≥30 mL/min/1.73 m\^2).) · Hazard ratio (hr): 0.26 · 95% CI 0.165 to 0.406
SecondaryNumber (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment

Rescue therapy included any use of RBC transfusion, ESA, or IV iron.

Time frame:
Baseline (Day 1, Week 0) up to Week 24 and up to Week 52
Reported as:
Count of participants · Participants
Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment
ParticipantsRoxadustatPlacebo
24 Weeks2961
52 Weeks5488
Statistical analysis
  • Roxadustat vs Placebo · Cox Proportional hazards model · p = <0.0001 (From a Cox Proportional hazards model adjusting for baseline Hb, baseline eGFR and the randomization stratification factors, except baseline Hb (\<=8 g/dL versus \>8 g/dL) and eGFR (\<30 versus \>=30 mL/min/1.73m\^2).) · Hazard ratio (hr): 0.17 · 95% CI 0.108 to 0.267
  • Roxadustat vs Placebo · Cox Proportional hazards model · p = <0.0001 (From a Cox Proportional hazards model adjusting for baseline Hb, baseline eGFR and other randomization stratification factors, except baseline Hb (≤8 g/dL versus \>8 g/dL) and eGFR (\<30 versus ≥30 mL/min/1.73 m\^2).) · Hazard ratio (hr): 0.19 · 95% CI 0.138 to 0.276
SecondaryChange From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28

The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). A higher score indicates a general improvement of life quality or well-being. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.

Time frame:
Baseline (Day 1, Week 0), Weeks 12 to 28
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28
scores on a scaleRoxadustatPlacebo
Physical functioning subscore: Baseline41.16 ± 10.12141.35 ± 10.070
Physical functioning subscore: Change at Weeks 12 to 280.33 ± 7.302-0.27 ± 7.363
Vitality subscore: Baseline48.19 ± 10.14647.62 ± 9.774
Vitality subscore: Change at Weeks 12 to 281.90 ± 8.7051.02 ± 8.334
SecondaryNumber (%) of Participants Who Experienced Exacerbation of Hypertension

Exacerbation of hypertension was defined as an increase from baseline of ≥20 millimeter of mercury (mmHg) in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥110 mmHg.

Time frame:
Baseline up to Week 52
Reported as:
Count of participants · Participants
Number (%) of Participants Who Experienced Exacerbation of Hypertension
ParticipantsRoxadustatPlacebo
Number (%) of Participants Who Experienced Exacerbation of Hypertension14048
SecondaryMean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28

Baseline MAP was defined as the last MAP value prior to the first dose of study drug.

Time frame:
Baseline, Weeks 20 to 28
Reported as:
Mean · mmHg
Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28
mmHgRoxadustatPlacebo
Baseline92.16 ± 8.53891.53 ± 8.077
Change at Weeks 20 to 280.02 ± 8.648-0.12 ± 7.653

Adverse events

Collected over Baseline (Day 1, Week 0) up to 28 days after the last dose of study drug (maximum treatment duration was 234.9 weeks for roxadustat and 208.1 weeks for placebo). Mortality presented is for the timeframe of Baseline (Day 1, Week 0) up to end of treatment (maximum treatment duration was 234.9 weeks for roxadustat and 208.1 weeks for placebo).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat38/611 (6.2%)321/611 (52.5%)468/611 (76.6%)
Placebo11/305 (3.6%)120/305 (39.3%)216/305 (70.8%)
Most frequent serious events
Showing 10 of 368
Most frequent serious events
EventRoxadustatPlacebo
Acute kidney injuryRenal and urinary disorders41/6116/305
End stage renal diseaseRenal and urinary disorders34/61110/305
PneumoniaInfections and infestations29/61112/305
Chronic kidney diseaseRenal and urinary disorders27/6119/305
Cardiac failure congestiveCardiac disorders23/6115/305
HyperkalemiaMetabolism and nutrition disorders19/6114/305
Urinary tract infectionInfections and infestations18/6118/305
AnemiaBlood and lymphatic system disorders5/6118/305
HyponatremiaMetabolism and nutrition disorders15/6113/305
PeritonitisInfections and infestations13/6111/305
Most frequent other events
Showing 10 of 32
Most frequent other events
EventRoxadustatPlacebo
ConstipationGastrointestinal disorders103/61134/305
HyperkalemiaMetabolism and nutrition disorders98/61138/305
Viral upper respiratory tract infectionInfections and infestations97/61140/305
Upper respiratory tract infectionInfections and infestations78/61148/305
HypertensionVascular disorders93/61126/305
Oedema peripheralGeneral disorders89/61128/305
NauseaGastrointestinal disorders85/61129/305
AnemiaBlood and lymphatic system disorders12/61139/305
DiarrhoeaGastrointestinal disorders77/61131/305
HeadacheNervous system disorders66/61126/305

Baseline characteristics

ITT Population included all randomized/enrolled participants.

Age, Categorical
Age, Categorical(Participants)RoxadustatPlaceboTotal
<=18 years000
Between 18 and 65 years271146417
>=65 years345160505
Sex: Female, Male
Sex: Female, Male(Participants)RoxadustatPlaceboTotal
Female375176551
Male241130371
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RoxadustatPlaceboTotal
Hispanic or Latino16584249
Not Hispanic or Latino451222673
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RoxadustatPlaceboTotal
American Indian/ Alaskan Native617
Asian310151461
Black/African American7628104
Native Hawaiian or Other Pacific Islander246
White17699275
Other462369
08

Study locations

145 sites
  • Investigational Site
    Huntsville, Alabama 35801, United States
  • Investigational Site
    Tempe, Arizona 85284, United States
  • Investigational Site
    Alhambra, California 91801, United States
  • Investigational Site
    Chula Vista, California 91910, United States
  • Investigational Site
    Inglewood, California 90301, United States
  • Investigational Site
    La Mesa, California 91942, United States
  • Investigational Site
    La Palma, California 91324, United States
  • Investigational Site
    Lynwood, California 90262, United States
  • Investigational Site
    Northridge, California 91325, United States
  • Investigational Site
    Paramount, California 90723, United States
  • Investigational Site
    Riverside, California 92503, United States
  • Investigational Site
    Roseville, California 95661, United States
  • Investigational Site
    San Dimas, California 91773, United States
  • Investigational Site
    Whittier, California 90603, United States
  • Investigational Site
    Coral Gables, Florida 33134, United States
  • Investigational Site
    Cutler Bay, Florida 33157, United States
  • Investigational Site
    Hialeah, Florida 33016, United States
  • Investigational Site
    Miami, Florida 33015, United States
  • Investigational Site
    Miami, Florida 33122, United States
  • Investigational Site
    Miami, Florida 33135, United States
  • Investigational Site
    Miami, Florida 33150, United States
  • Investigational Site
    Ocala, Florida 34471, United States
  • Investigational Site
    Pembroke Pines, Florida 33028, United States
  • Investigational Site
    South Miami, Florida 33143, United States
  • Investigational Site
    Winter Park, Florida 32789, United States
  • Investigational Site
    Augusta, Georgia 30909, United States
  • Investigational Site
    Caldwell, Idaho 83605, United States
  • Investigational Site
    Shreveport, Louisiana 71101, United States
  • Investigational Site
    Baltimore, Maryland 21218, United States
  • Investigational Site
    Boston, Massachusetts 02215, United States
  • Investigational Site
    Detroit, Michigan 48202, United States
  • Investigational Site
    Flint, Michigan 48503, United States
  • Investigational Site
    Flint, Michigan 48532, United States
  • Investigational Site
    Pontiac, Michigan 48341, United States
  • Investigational Site
    Roseville, Michigan 48066, United States
  • Investigational Site
    Saint Louis, Missouri 63110, United States
  • Investigational Site
    New Brunswick, New Jersey 08903, United States
  • Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Investigational Site
    Bronx, New York 10461, United States
  • Investigational Site
    Mineola, New York 11501, United States
  • Investigational Site
    Asheville, North Carolina 28801, United States
  • Investigational Site
    Raleigh, North Carolina 27609, United States
  • Investigational Site
    Rocky Mount, North Carolina 27804, United States
  • Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site
    Beaver, Pennsylvania 15009, United States
  • Investigational Site
    Orangeburg, South Carolina 29118, United States
  • Investigational Site
    Sumter, South Carolina 29150, United States
  • Investigational Site
    Nashville, Tennessee 37232, United States
  • Investigational Site
    Arlington, Texas 76015, United States
  • Investigational Site
    Corsicana, Texas 75110, United States
  • Investigational Site
    Dallas, Texas 75246, United States
  • Investigational Site
    Houston, Texas 77030, United States
  • Investigational Site
    San Antonio, Texas 78229, United States
  • Investigational Site
    Fairfax, Virginia 22033, United States
  • Investigational Site
    Morgantown, West Virginia 26506, United States
  • Investigational Site
    Ciudad Evita, Buenos Aires B1178IFA, Argentina
  • Investigational Site
    Moron, Buenos Aires B1708DPN, Argentina
  • Investigational Site
    González Catán, Provincia De Buenos Aires B1759LTF, Argentina
  • Investigational Site
    Junin, Provincia De Buenos Aires B6000GMA, Argentina
  • Investigational Site
    Pergamino, Provincia De Buenos Aires B2700CPM, Argentina
  • Investigational Product
    Villa Domínico, Provincia De Buenos Aires B1874GBA, Argentina
  • Investigational Site
    Ciudad de Cordoba, Provincia De Cordoba X5002HWE, Argentina
  • Investigational Site
    Buenos Aires, B1852FZD, Argentina
  • Investigational Site
    Buenos Aires, C1425BPJ, Argentina
  • Investigational Site
    Buenos Aires, C1429BWN, Argentina
  • Investigational Site
    Cordoba, 5000, Argentina
  • Investigational Site
    Cordoba, X5002AOQ, Argentina
  • Investigational site
    Cordoba, X5016KET, Argentina
  • Investigational Site
    Corrientes, 3400, Argentina
  • Investigational Site
    Mendoza, 5500, Argentina
  • Investigational Site
    Salta, A4402BGJ, Argentina
  • Investigational Site
    Santa Fe, 3000, Argentina
  • Investigational Site
    Liverpool, New South Wales 2170, Australia
  • Investigational Site
    Gosford, 2250, Australia
  • Investigational Site
    Hobart, 7000, Australia
  • Investigational Site
    Launceston, 7250, Australia
  • Investigational Site
    Melbourne, 3004, Australia
  • Investigational Site
    New Lambton Heights, 2305, Australia
  • Investigational Site
    Randwick, 2031, Australia
  • Investigational Site
    Temuco, Region De La Araucania 4781151, Chile
  • Investigational Site
    Santiago, Region Metropolitana 8431657, Chile
  • Investigational Site
    Barranquilla, Atlantico, Colombia
  • Investigational Site
    Bogota, Cundinamarca, Colombia
  • Investigational Site
    Hong Kong, Pokfulam, Hong Kong
  • Investigational Site
    Chai Wan, Hong Kong
  • Investigational Site
    Shatin, 852, Hong Kong
  • Investigational Site
    Tai Po, Hong Kong
  • Investigational Site
    Anyang-Si, Gyeonggi-Do 431-796, Korea, Republic of
  • Investigational Site
    Goyang-Si, Gyeonggi-Do 410-719, Korea, Republic of
  • Investigational Site
    Guri-Si, Gyeonggi-Do 471-701, Korea, Republic of
  • Investigational Site
    Seongnam-Si, Gyeonggi-Do 463-712, Korea, Republic of
  • Investigational Site
    Busan, 614-735, Korea, Republic of
  • Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Investigational Site
    Seoul, 130-872, Korea, Republic of
  • Investigational Site
    Seoul, 133-791, Korea, Republic of
  • Investigational Site
    Seoul, 134-727, Korea, Republic of
  • Investigational Site
    Seoul, 137-701, Korea, Republic of
  • Investigational Site
    Seoul, 143-729, Korea, Republic of
  • Investigational Site
    Seoul, Korea, Republic of
  • Investigational Site
    Alor Setar, 05460, Malaysia

Showing the first 100 of 145 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Little DJ, Houser MT, Frison L, Houghton J, Neff TB. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol. 2021 Aug;16(8):1190-1200. doi: 10.2215/CJN.16191020. PubMed 34362786 ↗
  • Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, Chan TM, Besarab A, Chou W, Bradley C, Eyassu M, Leong R, Lee TT, Saikali KG, Szczech L, Yu KP. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep. 2020 Dec 5;6(3):624-635. doi: 10.1016/j.ekir.2020.11.034. eCollection 2021 Mar. PubMed 33732977 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Sep 2018, 70 months.

Results were first posted in Oct 2021, 3 years after primary completion. A results delay was requested in Oct 2019.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 70 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2012
First posted
Dec 17, 2012
StartActual
Nov 5, 2012
Primary completionActual
Sep 24, 2018
CompletionActual
Sep 24, 2018
Results delay requested
Oct 23, 2019
Results first posted
Oct 1, 2021
Last update
Oct 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01750190
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Dec 17, 2012
Start date
Nov 5, 2012
Primary completion
Sep 24, 2018
Completion
Sep 24, 2018
Results posted
Oct 1, 2021
Last update
Oct 1, 2021

Study contacts

Mark Eisner, MD, MPH
study chair · FibroGen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion